Please ensure Javascript is enabled for purposes of website accessibility

This Oral MS Drug Is Off to a Quick Start

By Brian Orelli, PhD – Mar 16, 2014 at 6:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Biogen Idec's Tecfidera is succeeding where Novartis and Sanofi struggled.

Biogen Idec's (BIIB 1.34%) Tecfidera wasn't the first oral multiple sclerosis drug, but is sure has gotten off to a much faster start than Novartis' (NVS 1.09%) Gilenya, which was approved by the FDA in 2010 and Sanofi's (SNY 0.75%) Aubagio, which was approved in 2012.

In its third quarter on the market, Biogen registered nearly $400 million in sales, putting it well on its way to achieving blockbuster status. It's not hard to see Tecfidera catching more established injected drugs such as Teva Pharmaceuticals' Copaxone and Biogen Idec's own Avonex.

In the following video, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss why Biogen Idec got off to such a quick start where Novartis and Sanofi couldn't.

Brian Orelli and Max Macaluso, Ph.D., have no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.